Autopsy report · NCT05744557

Vapocoolant Analgesia for Breast Lymphoscintigraphy

“\<75% accrued participants”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 30 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

num Vapocoolant

Participants

30

Sites

1

Countries

United States

Trials that died the same way

• ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
  “\<75% participants” (78% match in meaning)
• Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
  “\< 75% participation” (76% match in meaning)
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
  “Low participant accrual” (61% match in meaning)
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
  “0 participant accrual” (58% match in meaning)
• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
  “lack of participant accrual” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.